摘要
α-干扰素是治疗慢性丙型肝炎的基本药物,但是应用α-干扰素单一疗法的治疗终末病毒应答率只有30%左右,持续病毒应答率仅约10%.
出处
《临床肝胆病杂志》
CAS
北大核心
2003年第1期5-7,共3页
Journal of Clinical Hepatology
参考文献14
-
1[1]McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha - 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].N EngJ Med, 1998, 339:1485- 1492.
-
2[2]Saracco G, Borghesio E, Mesina P, etal. Prolonged treatment (2 years)with different doses (3 versus 6 MU) of interferon alpha- 2b for chronic hepatitis C. Results of a multicenter randomized trial [J]. J Hepatol,1997, 27:56-62.
-
3[3]Roberts MJ, Harris JM. Attachment of degradable poly (ethylene glycol)to proteins has the potential to increase therapeutic efficacy[J]. J Pharm Sci, 1998, 87:1440- 1445.
-
4[4]Zeuzem S. Clinical implications of hepatitis C viral kinetics[J].J Hepatol, 1999, 31(Suppll):61-64.
-
5[5]Neumann AU, Lam NP, Dahari H, etal. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon - α therapy [J]. Science,1998, 282:103 - 107.
-
6[6]Monkarsh SP, Ma Y, Aglione A, etal. Positional isomers of monopegy-lated interferon alpha -2a: isolation, characterization, and biological ac-tivity[J].Anal Biochem, 1997, 247:434-440.
-
7[7]Zeuzam S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a[J].Gastroenterology, 2001, 120:1438 - 1447.
-
8[8]Reddy KR, Wright TL, Pockros PJ, etal. Efficacy and safety of pegylated (40- kd) interferon alpha- 2a compared with interferon alpha- 2a in noncirrhotc patients with chronic hepatitis C[J].Hepatolgy, 2001, 33:433 - 438.
-
9[9]Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa- 2a in patients with chronic hepatitis C [J].N Engl J Med, 2000, 343:1666-1672.
-
10[10]Lindsay KL, Trepo C, Heintges T, et al. A randomized, double- blind trial comparing pegylated interferon alfa- 2b to interfern alfa- 2b as inirial treatment for chronic hepatitis C[J]. Hepatology, 2001,34: 395 -403.
同被引文献15
-
1马秀云.长效干扰素的相关不良反应[J].药物不良反应杂志,2004,6(5):312-315. 被引量:13
-
2张鸿飞,杨晓晋,朱世殊,董漪,陈大为,贾文峥,徐志强,毛远丽,唐红梅.聚乙二醇α干扰素治疗54例小儿慢性丙型肝炎报道[J].中华实验和临床病毒学杂志,2005,19(2):185-187. 被引量:16
-
3鞠洋,路莉,吴勇杰,高明堂,李文广,闵光宁.ELISA法研究新型重组人肿瘤坏死因子在小鼠体内的药代动力学[J].中国药理学通报,2005,21(7):847-851. 被引量:6
-
4曹振环(编译).24周长效干扰素联合利巴韦林是治疗HCV基因2型和3型的最佳方案[J].传染病网络动态,2007(9):5-5. 被引量:1
-
5Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C[J].N Eng 1 Jmed, 2000,J 343 (23) : 1666-1672.
-
6Osbom B L, Olsen H S, Nardelli B, et al. Phar-macokinetic and pharmacodynamic studies of a human serum albumin-Interferon-α Fusion protein in cynomolgus monkeys[ J]. J Pharmacol Exp Ther, 2002,303 (2) : 540 - 8.
-
7Bailon P, Palleroni A, Schaffer C A, et al. Rational design of a potent, long-lasting form of interferon : A 40 kDa branchedpolyethylene glycol-conjugated interferon α2a for the treatment of Hepatitis C [ J ]. Bioconjug Chem,2001,12 (2) : 195 - 202.
-
8Peoinsky R B,Lepage D J, Gil A,et al. Improved Pharmacokinetic propertiesof a polyethylene glycol-modified form of in-terferon-β-1a with preserved in vitro bioactivity[ J]. J Pharmacol Exp Ther, 2001,297(3 ) :1059 -66.
-
9HGS press release. Human Genome clinical trial of albuferon^TM in treatment-naive patients with chronic hepatitis C [ R ]. February 16, 2005.
-
10Balan V . Safety, pharmacokinetics and pharmacodynamic results of higher doses of Albuferon (tm) in a phase 1/2 single and double dose-escalation study in treatment experienced subjects with chronic hepatitis C[ R]. 39th Annual Meeting of the European Association for the Study of the Liver, Berlin. April 15, 2004.
引证文献3
-
1唐红梅,张鸿飞,朱世殊,董漪,马翠新.聚乙二醇干扰素注射局部的反应及处理[J].护士进修杂志,2007,22(16):1493-1494. 被引量:5
-
2邢文会,杨萍,汪海霞,杨健良.猕猴体内白蛋白融合干扰素α-2b(HSA-IFNα-2b)的药代动力学研究[J].中国药理学通报,2007,23(9):1156-1160. 被引量:4
-
3李云霞.长效干扰素治疗慢性丙型肝炎临床分析[J].医药论坛杂志,2010,31(24):85-86. 被引量:1
二级引证文献10
-
1徐丙发,范清林,魏伟,宋礼华.干扰素-α及长效干扰素抗肝炎病毒作用机制的研究进展[J].中国药理学通报,2008,24(10):1276-1279. 被引量:27
-
2李文德,吴玉娥,闵凡贵,李卓,黄家园,黄韧.淀粉样β-蛋白1-42和thiorphan对恒河猴海马结构的影响[J].中国药理学通报,2010,26(2):186-190. 被引量:1
-
3高丹凤,王岚.干扰素治疗慢性乙型肝炎的护理进展[J].护理学报,2010,17(22):17-19. 被引量:13
-
4蒋孟军,周尧远,张荣军,蔡刚明,顾晓波.人血清白蛋白融合干扰素α2b体外抑制乙肝病毒的实验研究[J].中国医院药学杂志,2012,32(2):100-103.
-
5何梅,李芳.聚乙二醇干扰素致过敏反应1例[J].药物流行病学杂志,2012,21(7):345-345. 被引量:3
-
6王蔚,尹有美,于立新.慢性丙型肝炎两种治疗方案的成本-效果分析[J].现代医药卫生,2012,28(21):3240-3241. 被引量:3
-
7付晓云,付霞,冯宇,蒋磊,刘建,常维山.不同种属干扰素对肉仔鸡疫苗免疫的调节作用[J].山东畜牧兽医,2013,34(2):3-4.
-
8赵亚婷,张景华,张显岚.乳腺癌动物模型的现状及进展[J].中国煤炭工业医学杂志,2013,16(8):1417-1421. 被引量:3
-
9张天镇,王刚,许红玉.聚乙二醇干扰素致皮肤局部过敏1例[J].中国煤炭工业医学杂志,2013,16(8):1421-1421. 被引量:1
-
10朱世殊,董漪.慢性丙型肝炎儿童抗病毒治疗现状及进展[J].中华实用儿科临床杂志,2017,32(10):727-729.
-
1Moreno A.,Bárcena R.,Garca-Garzón S.,李宏宇.聚乙二醇干扰素α-2b联用利巴韦林对单纯基因1型HCV感染、合并HIV感染和肝移植患者HCV的清除和治疗结果[J].世界核心医学期刊文摘(胃肠病学分册),2006,0(3):57-58.
-
2王丽旻,张鸿飞.聚乙二醇干扰素治疗非普通型慢性丙型肝炎有关进展[J].中华医学杂志,2007,87(18):1293-1296. 被引量:1
-
3窦以志,高翠玲,曹长安.聚乙二醇干扰素α-2a治疗慢性丙型肝炎合并糖尿病疗效观察[J].中国实用医刊,2011,38(10):85-86. 被引量:2
-
4郭芙蓉,吴超.干扰素治疗慢性丙型肝炎合并糖尿病的临床分析[J].中国社区医师,2015,31(14):41-41. 被引量:1
-
5王爱敏,赵晶.思密达与锡类散联用治疗溃疡性结肠炎的临床观察[J].中华腹部疾病杂志,2004,4(4):278-278.
-
6美国呼吁采用“预防性鸡尾酒疗法”降低MSM中的HIV感染率[J].中国艾滋病性病,2008,14(2):172-172. 被引量:1
-
7项荣,张建安,白骕,施京军.胸腺肽联合三联疗法治疗幽门螺杆菌感染50例[J].中国老年学杂志,2014,34(24):7100-7100. 被引量:1
-
8李振环.综合疗法治疗类风湿关节炎临床体会[J].中国社区医师(医学专业),2004,6(22):55-57.
-
9贺芳.中国与美国FDA先后批准派罗欣用于治疗慢性乙肝[J].中华医学信息导报,2005,20(13):11-11.
-
10池肇春.抗HCV治疗无反应患者的治疗[J].临床肝胆病杂志,2006,22(1):16-18. 被引量:3